Acamprosate in Alcoholics With Comorbid Anxiety or Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00330174
Recruitment Status : Completed
First Posted : May 26, 2006
Results First Posted : April 13, 2015
Last Update Posted : April 13, 2015
Mclean Hospital
Columbia University
Information provided by (Responsible Party):
Susan Sonne, Medical University of South Carolina

May 25, 2006
May 26, 2006
May 29, 2013
April 13, 2015
April 13, 2015
April 2006
September 2010   (Final data collection date for primary outcome measure)
Percent Days Drinking [ Time Frame: 12 weeks ]
Drinking was assessed using the timeline followback (TLFB), which is a calendar-based instrument used to assess drinking and other substance use on a daily basis.
Total days abstinent from alcohol
Complete list of historical versions of study NCT00330174 on Archive Site
  • Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: 12 weeks ]
    This 10-item rating scale is commonly used in the European pharmacotherapy trials, and it may have benefit in assessing substance abusers, because it focuses on cognitive symptoms of depression instead of the physical symptoms, which could be due to substance use and withdrawal (Yonkers and Samson, 2000). Total scores are used; Scale range is 0-60, with higher scores reflecting more severe symptoms.
  • Liebowitz Social Anxiety Scale [ Time Frame: 12 weeks ]
    The LSAS is a 24-item semi-structured clinician-administered instrument that assesses social anxiety through the evaluation of fear and avoidance of different social and performance situations. There are two subscales (avoidance and fear), with scores ranging from 0-72; Total score for instrument ranges from 0-144. This study only reports on total score. Higher scores reflect greater anxiety symptoms.
  • Hospital Anxiety and Depression Scale [ Time Frame: 12 weeks ]
    This is a 14-item self report assessment that contains two subscales (depression and anxiety) with each subscale ranging from 0-21; the total score ranges from 0-42. We report total scores. Higher scores represent worse symptoms.
  • Liebowitz Social Anxiety Scale
  • Hospital Anxiety and Depression Scale
  • CGI
Not Provided
Not Provided
Acamprosate in Alcoholics With Comorbid Anxiety or Depression
The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression


The primary objective of this study is to compare the safety and efficacy of acamprosate versus placebo in the treatment of alcohol dependence in adults with co-occurring mood or anxiety disorders (specifically, depression (MDE), generalized anxiety disorder (GAD) or social anxiety disorder). Secondary objectives are to evaluate the effect of acamprosate treatment on mood and anxiety disorders.


This is a randomized, double-blind, placebo-controlled trial evaluating acamprosate in the treatment of alcohol dependence in adult outpatients with concurrent mood and/or anxiety disorders. The active study phase will be 12 weeks in duration. There will be a two-week screening period, followed by 12 weeks of study medication and a follow-up assessment at 14 weeks from randomization.


A total of 90 (30 per site) men and women aged 18-60 years who have a current diagnosis of alcohol dependence as well as a current DSM-IV diagnosis of either MDE, GAD and/or social anxiety will be recruited to participate in this study. Only those individuals whose psychiatric disorders are stable will be randomized to acamprosate or placebo. Three sites will participate in this trial.


Eligible participants will be randomly assigned to receive either acamprosate or matching placebo for 12 weeks.


The primary efficacy outcome measure will be cumulative days abstinent as measured by self-report.

Participants who meet all inclusion criteria and none of the exclusion criteria will be randomized to receive either acamprosate or placebo in a 1:1 ratio. Participants will be instructed to take (2) 333 mg tablets three times a day. Participants will be seen weekly for 12 weeks an again 14 weeks from randomization. At each weekly visit, participants will be asked about substance use and possible adverse events. They will also have their vital signs and weight measured at each visit. Psychiatric assessments, including the MADRS,HAM-A, Liebowitz Social Anxiety Scale, and Hospital Anxiety and Depression Scale will be performed at weeks 2, 4, 8, and 12. Alcohol craving will be assessed using the Obsessive Compulsive Drinking Scale at baseline and monthly. A urine drug screen will also be performed monthly. A clinical global impressions scale will be completed for both psychiatric and alcohol abuse symptoms at every visit. A breath alcohol test will be performed at every visit, and a urine drug screen will be performed at baseline and monthly during the trial.
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Alcohol Dependence
  • Major Depression
  • Social Anxiety Disorder
  • Generalized Anxiety Disorder
Drug: Acamprosate
2 333mg tablets three times daily
  • Experimental: 1
    Acamprosate tablets
    Intervention: Drug: Acamprosate
  • Placebo Comparator: 2
    Matching placebo tablets
    Intervention: Drug: Acamprosate
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
September 2010
September 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Adults ages 18-60
  2. Meet DSM-IV criteria for current (past 90 days) alcohol dependence
  3. Must identify alcohol as the primary substance of abuse
  4. Meet DSM-IV criteria for a current major depressive episode, GAD and/or social anxiety disorder
  5. Have a stable psychiatric condition, as evidenced by a baseline CGI change score of 4 or below between the time of initial screening and the baseline visit, and if receiving psychotropic medication, must have a stable dose of medication for at least one month prior to baseline.
  6. Must have a negative urine drug screen at the baseline visit; UDS may be repeated no more that twice to obtain an negative UDS
  7. May be receiving medication treatment for anxiety/mood disorder as long as the dosage has been stable for 4 weeks prior to randomization.
  8. May be engaged in psychosocial treatment for alcohol dependence or for mood/anxiety disorders.
  9. Must abstain from alcohol for at least 3 consecutive days but no more than 21 days prior to medication initiation
  10. Subjects must be able to adequately provide informed consent and function at an intellectual level sufficient to allow the accurate completion of all assessment instruments
  11. Subjects must consent to random assignment, be willing to commit to medication treatment and follow-up assessments
  12. CIWA-Ar scale is 8 or less at the baseline visit

Exclusion Criteria:

  1. Individuals with a primary psychotic disorder or bipolar disorder
  2. Individuals who meet DSM-IV criteria for current (past 90 days) dependence on substances other than alcohol, caffeine or nicotine
  3. Individuals with an uncontrolled neurologic condition that could confound the results of the study
  4. Individuals with an uncontrolled medical condition that may adversely affect the conduct of this trial or jeopardize the subject's safety
  5. Regular use of benzodiazepines for the treatment of psychiatric symptoms (as defined as more than 12 times in the month prior to the screening visit)
  6. Individuals receiving pharmacotherapy (e.g. disulfiram or naltrexone) for prevention of alcohol relapse
  7. Women of childbearing potential who are lactating or refuse to use adequate forms of birth control
  8. Current suicidal or homicidal risk
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Susan Sonne, Medical University of South Carolina
Medical University of South Carolina
  • Mclean Hospital
  • Columbia University
Principal Investigator: Susan C Sonne, PharmD, BCPP Medical University of South Carolina
Principal Investigator: Jennifer S Potter, PhD Mclean Hospital
Principal Investigator: Richard Rosenthal, MD Columbia University College of Physicians & Surgeons
Medical University of South Carolina
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP